Your AI-Trained Oncology Knowledge Connection!
Data from the phase 3 PEARL trial indicated that durvalumab yielded a clinically significant improvement in overall survival but did not meet statistical significance among patients with stage IV non–small cell lung cancer with high PD-L1 expression.
Positive topline data from the phase 2b HERIZON-BTC-01 trial indicate zanidatamab may improve outcomes for patients with HER2-amplified and expressing biliary tract cancers.
Despite the observed disease-free survival benefit associated with pembrolizumab in high-risk kidney cancer after surgery, the European Association of Urology guidelines maintain a weak recommendation for its use.
Olaparib in combination with abiraterone and prednisone or prednisolone alone has been approved as treatment for metastatic castration-resistant prostate cancer in the European Union.
Treatment with the BTK inhibitor ibrutinib plus the CAR-T cell therapy tisagenlecleucel produced a high rate of durable responses in patients with relapsed/refractory mantle cell lymphoma after they stopped treatment at 6 months, according to early data from the TARMAC trial.
A panel of experts from Mount Sinai examines representative patient cases and reviews treatments in multiple myeloma.
Kendra Sweet, MD, discussed several ongoing studies in chronic myeloid leukemia, with some initial results presented at the 2022 American Society of Hematology Annual Meeting and Exposition.
Elle Charnisky, a patient with stage IV HER2+ metastatic colorectal cancer (mCRC), joins a panel of healthcare professionals to discuss how HER2 alternations are detected and how patients with HER2+ mCRC are optimally treated to improve outcomes.
Judy C. Boughey, MD; Robert Mutter, MD; and Siddhartha Yadav, MD, MBBS, of Mayo Clinic spoke with CancerNetwork® multidisciplinary findings presented at the 2022 San Antonio Breast Cancer Symposium, ranging from surgery to radiotherapy to biomarker research.
An expert from the University of Texas Southwestern Medical Center questions how providers are currently utilizing stereotactic radiation in the treatment of metastatic kidney cancer.
Bradford S. Hoppe, MD, MPH, and Omran Saifi, MD, offer a peer perspective on research by Gavin Jones, MD, and colleagues into radiation therapy in diffuse large B-cell lymphoma.
Patients with kidney cancer should be made aware of trials that have not read out positively in the adjuvant setting, according to an expert from the Royal Free London NHS Foundation Trust.
Experts present patient cases of those with transplant-eligible or ineligible multiple myeloma and discuss the current standard of care treatment, and how to apply it to their patients.
Kendra Sweet, MD, examined how the data surrounding asciminib in chronic myeloid leukemia will affect the standard of care treatment options.
Acalabrutinib produced promising response rates in combination with lenalidomide and rituximab in previously untreated patients with mantle cell lymphoma.
Co-editor-in-Chief Howard S. Hochster, MD, reviews the major clinical and scientific developments of 2022 in the oncology space.
Kendra Sweet, MD, discussed results of the the phase 2 OPTIC trial, which investigated ponatinib in a group of patients with resistant, chronic phase chronic myeloid leukemia.
Expert hematologist-oncologists discuess the E7438-G000-101 clinical trial and consider the EZH2 inhibitor tazemetostat as a treatment for relapsed/refractory follicular lymphoma.
The FDA’s decision to approve mosunetuzumab marks the first bispecific antibody approved to treat follicular lymphoma.
The FDA granted breakthrough therapy designation to adagrasib plus cetuximab for patients with KRAS G12C–mutated advanced colorectal cancer based on findings from the phase 1b cohort of the KRYSTAL-1 trial.
Experts from leading institutions debate the latest advances in multiple myeloma.
Following the 2022 ASH Annual Meeting and Exposition, Peter Voorhees, MD; Amrita Krishnan, MD; and Josh Richter, MD, participated in a rapid-fire question-and-answer 2-Minute Drill program, hosted by CancerNetwork®. Topics ranged from most exciting data in blood cancer, as well as what research needs more follow-up.
Alberto Calvo-García, PharmG, and colleagues analyzed routinely-collected data to assess regorafenib in metastatic colorectal cancer.
The findings, according to a third-party expert, suggest there’s no benefit to the use of trifluridine and tipiracil alone in earlier lines of therapy for the treatment of colon cancer.
Patients with HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma in the European Union can now receive treatment with fam-trastuzumab deruxtecan-nxki following its approval.
The FDA has approved the FoundationOne Liquid CDx as a companion diagnostic for identifying patients with non-small cell lung cancer harboring EGFR mutations who may benefit from treatment with specific tyrosine kinase inhibitors.
Ongoing clinical trials are exploring the cytoreductive properties and immunogenic potential of stereotactic radiation in the treatment of patients with metastatic kidney cancer, according to an expert from the University of Texas Southwestern Medical Center.
Gavin Jones, MD, and colleagues explore the landscape of radiation therapy in diffuse large B-cell lymphoma.
Results from the phase 2 ARC-7 trial found that zimberelimab, etrumadenant, and domvanalimab enhanced efficacy outcomes in patients with advanced non–small cell lung cancer.
The FDA has set the Prescription Drug User Fee Act date for April 21, 2023 for each supplemental biologics license application of enfortumab vedotin-ejfv and pembrolizumab in urothelial carcinoma.
